If the data are beyond any hint of rapproach, they'll get Fast Track. If not, they'll get full review. I think it has next to nothing to do with superiority/non-inferiority. Given the political heat about this drug and trial, deserved or undeserved it does not matter, I would be very surprised to see a 6-month review.
Market Data 
Markets 
AI
